ArticleFrontiers in oncology2022
DeepLN: A Multi-Task AI Tool to Predict the Imaging Characteristics, Malignancy and Pathological Subtypes in CT-Detected Pulmonary Nodules.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Self-reporting with checklists in artificial intelligence research on medical imaging: a systematic review based on citations of CLAIM.European radiology · 2024Pooled it
- Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes.Journal of cancer research and clinical oncology · 2026Review
- Imaging Features of Lung Ground-Glass Nodules and Their Correlation With Biological Behavior.Cureus · 2025Review
- Mapping the research trends and hotspots on solid pulmonary nodules from 2000-2024: insights from bibliometric analysis.Journal of thoracic disease · 2025Article
- Artificial intelligence-based deep learning algorithms for ground-glass opacity nodule detection: A review.Narra J · 2025Review
- Artificial Intelligence-Empowered Radiology-Current Status and Critical Review.Diagnostics (Basel, Switzerland) · 2025Review
- Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters.Frontiers in oncology · 2025Article
- Novel tools for early diagnosis and precision treatment based on artificial intelligence.Chinese medical journal pulmonary and critical care medicine · 2023Review
- The effect of spatial resolution on deep learning classification of lung cancer histopathology.BJR open · 2023Article
- Developing a weakly supervised deep learning framework for breast cancer diagnosis with HR status based on mammography images.Computational and structural biotechnology journal · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Distinction of malignant pulmonary nodules from the benign ones based on computed tomography (CT) images can be time-consuming but significant in routine clinical management. The advent of artificial intelligence (AI) has provided an opportunity to improve the accuracy of cancer risk prediction. Methods: A total of 8950 detected pulmonary nodules with complete pathological results were retrospectively enrolled. The different radiological manifestations were identified mainly as various nodules densities and morphological features. Then, these nodules were classified into benign and malignant groups, both of which were subdivided into finer specific pathological types. Here, we proposed a deep convolutional neural network for the assessment of lung nodules named DeepLN to identify the radiological features and predict the pathologic subtypes of pulmonary nodules. Results: In terms of density, the area under the receiver operating characteristic curves (AUCs) of DeepLN were 0.9707 (95% confidence interval, CI: 0.9645-0.9765), 0.7789 (95%CI: 0.7569-0.7995), and 0.8950 (95%CI: 0.8822-0.9088) for the pure-ground glass opacity (pGGO), mixed-ground glass opacity (mGGO) and solid nodules. As for the morphological features, the AUCs were 0.8347 (95%CI: 0.8193-0.8499) and 0.9074 (95%CI: 0.8834-0.9314) for spiculation and lung cavity respectively. For the identification of malignant nodules, our DeepLN algorithm achieved an AUC of 0.8503 (95%CI: 0.8319-0.8681) in the test set. Pertaining to predicting the pathological subtypes in the test set, the multi-task AUCs were 0.8841 (95%CI: 0.8567-0.9083) for benign tumors, 0.8265 (95%CI: 0.8004-0.8499) for inflammation, and 0.8022 (95%CI: 0.7616-0.8445) for other benign ones, while AUCs were 0.8675 (95%CI: 0.8525-0.8813) for lung adenocarcinoma (LUAD), 0.8792 (95%CI: 0.8640-0.8950) for squamous cell carcinoma (LUSC), 0.7404 (95%CI: 0.7031-0.7782) for other malignant ones respectively in the malignant group. Conclusions: The DeepLN based on deep learning algorithm represented a competitive performance to predict the imaging characteristics, malignancy and pathologic subtypes on the basis of non-invasive CT images, and thus had great possibility to be utilized in the routine clinical workflow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.